[Form 4] Becton, Dickinson and Co. Insider Trading Activity

Rhea-AI Filing Summary

Michael Feld, EVP & President, Life Sciences at Becton, Dickinson & Co. (BDX), reported the sale of 57 shares of common stock on 08/22/2025 at a price of $197.99 per share, leaving him with 8,360 shares beneficially owned. The filing notes the sale was made pursuant to a Rule 10b5-1 plan adopted on August 2, 2024, indicating a prearranged, compliant insider trading plan.

Insights

Financial Analyst

TL;DR: A small, prearranged insider sale under a 10b5-1 plan; immaterial to company fundamentals.

The reported sale of 57 shares at $197.99 is nominal relative to total outstanding shares and does not alter Michael Feld's remaining stake of 8,360 shares in any material way. The use of a 10b5-1 plan reduces the likelihood the sale was based on undisclosed material information. For investors, this transaction is routine and non-informative about operational performance or outlook.

Corporate Governance Expert

TL;DR: Governance procedure followed: transaction executed under a documented 10b5-1 plan and reported on Form 4.

The filing demonstrates adherence to insider trading policies and timely disclosure. The Form 4 shows the transaction was processed under a plan adopted on August 2, 2024, and the form was signed via power of attorney on 08/26/2025. This reflects proper governance and disclosure practices but carries no material corporate governance implications beyond routine compliance.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Feld Michael

(Last) (First) (Middle)

C/O BECTON, DICKINSON AND COMPANY

1 BECTON DRIVE

(Street)

FRANKLIN LAKES NJ 07417

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BECTON DICKINSON & CO [ BDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & President, Life Sciences

3. Date of Earliest Transaction (Month/Day/Year)
08/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/22/2025		S		57	D	$197.99	8,360	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 2, 2024.

	Donna Kalazdy, by power of attorney from Michael Feld	08/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Michael Feld (BDX) sell and when?

He sold 57 shares of BDX common stock on 08/22/2025 at a price of $197.99 per share.

How many BDX shares does Michael Feld own after the sale?

The Form 4 reports he beneficially owned 8,360 shares following the reported transaction.

Was the sale part of a planned insider program for BDX?

Yes. The filing states the transaction was made pursuant to a Rule 10b5-1 plan adopted on August 2, 2024.

Who signed the Form 4 for Michael Feld and when was it filed?

The Form 4 was signed by Donna Kalazdy by power of attorney for Michael Feld and dated 08/26/2025.

Does this Form 4 indicate any material change to BDX's operations or finances?

No. The filing documents a small insider sale and contains no operational or financial disclosures about BDX.